ESTRO 37 Abstract book

S775

ESTRO 37

Results 54 patients (55.6%) were sarcopenic. There were 50 deaths in sarcopenic patients (92.6%) versus 26 deaths in non sarcopenic patients (60.5%). The median overall survival was 21.5 months in sarcopenic patients versus 61.3 months in no sarcopenic patients (p<0.001). Sarcopenia (SMI), BMI<21, NRI<97.5, and WHO status>0 were the only significant features in univariate analysis. In multivariate analysis sarcopenia was the only significant independent prognostic factor (HR=2.32[1.24- 4.34], p=0.008). We couldn’t define an optimal cut-off for Fat Free Mass and Sub-Cutaneous Fat Mass.

Conclusion By eliminating the effect of respiratory motion on the heart, 4DCT can better reflect the change of cardiac volume during radiotherapy of esophageal cancer. Heart volume was significantly reduced in the early treatment stage and maintained the reduction until the middle treatment stage, then showed a tendency to restore to the initial level at the thirtieth fraction. The blood pressure decreased and the heart rate increased during radiotherapy. These observed changes may be valuable indicators of cardiac impairment and target dose changes. EP-1424 Impact of sarcopenia in patients treated by radiochemotherapy for a Advanced Esophageal Cancer R. MALLET 1 , R. Modzelewski 2 , J. Lequesne 3 , H. Auvray 1 , A. Benyoucef 1 , F. Di Fiore 4 , P. Vera 2 , B. Dubray 1 , S. Thureau 1 1 Centre Henri Becquerel, Radiation Therapy, Rouen, France 2 Centre Henri Becquerel, Nuclear Medicine, Rouen, France 3 Centre Henri Becquerel, Clinical Research, Rouen, Franc 4 Centre Henri Becquerel, Medical Oncology, Rouen, France Objective Sarcopenia is a prognostic factor for patients operated for oesophageal cancer. However, the impact of sarcopenia hadn’t been explored for patients treated by exclusive curative radiochemotherapy for a locally advanced oesophageal cancer. This study tries to Method Clinical, nutritional, anthropometrics and functional- imaging (on 18 FDG-PET/CT) data were collected on 97 patients treated for a locally advanced oesophageal cancer between 2006 and 2012. L3-Skeletal Muscle was segmented on L3 cross-sectional CT images and normalized by patient’s height (SML3/h²) to obtain Skeletal Muscle Indice (SMI). Sarcopenia was defined by sex specific cut-off: SMI <38.5cm²/m² for women and 52.4cm²/m² for men. The primary end point was the overall survival. Secondary end points were to define a Fat Free Mass and Sub-Cutaneous Fat Mass optimal cut-off to predict the overall survival.

Conclusion Sarcopenia is a powerful independent prognostic factor, associated with a rise of the overall mortality in patients treated by exclusive radiochemotherapy for a locally advanced oesophageal cancer. PET-CT images are easily gathering data and can allow one to identify population at risk who needed an adapted therapy. EP-1425 Clinical implications of a novel iron- containing fiducial marker in radiotherapy for liver tumors. H. Doi 1,2 , S. Harui 1 , A. Sugimoto 1 , M. Fujiwara 1 , K. Kamino 1 , T. Nakajima 3 , S. Ikuta 3 , T. Aihara 3 , N. Yamanaka 3 , Y. Hishikawa 1 1 Meiwa Cancer Clinic, Department of Radiation Oncology, Nishinomiya, Japan 2 Kindai University Faculty of Medicine, Department of Radiation Oncology, Osaka-Sayama, Japan 3 Meiwa Hospital, Department of Surgery, Nishinomiya, Japan Purpose or Objective A 0.5%-iron-containing fiducial marker has been recently reported to have a high visibility in magnetic resonance imaging (MRI) and is possibly superior to markers containing no iron. However, only a few reports have reported the clinical implications of the 0.5%-iron- containing fiducial marker in radiotherapy for liver tumors. In this study, we report our findings regarding the utility of a 0.5%-iron-containing fiducial marker, Gold Anchor TM (GA; Naslund Medical AB, Huddinge, Sweden), in radiotherapy for liver tumors from our initial experience. Material and Methods Our institutional review board approved data collection and analysis (Approval No. 28–35). From June 2016 to March 2017, the data of four consecutive patients with liver tumors were retrospectively analyzed in this study. All of the patients provided written informed consent